Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on September 25, 2008. The report details the entry into a material definitive agreement with the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) for the development of an anthrax vaccine containing rPA and CpG immunostimulant.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of the new government contract.
- Base Period Funding: Up to approximately $13.2 million (includes cost reimbursement and fixed fees).
- Total Potential Value: Up to approximately $83.9 million (contingent on milestone achievement and option exercises).
Material Changes and Contract Structure
The primary material change is the execution of the NIAID agreement. The contract is incrementally funded and structured as follows:
- Base Period (3 Years): Covers pre-clinical activities including stability testing, toxicology in two animal species, and safety/immunogenicity testing.
- Option 1 (2 Years): Dose response study; value up to $6.1 million.
- Option 2 (2 Years): Phase I clinical trial; value up to $3.6 million.
- Option 3 (5 Years): Scale-up and validation; value up to $37.5 million.
- Option 4 (3 Years): Phase II clinical trial; value up to $23.5 million.
All option values consist of cost reimbursement and fixed fee components based on milestone events. NIAID retains sole discretion to exercise these options.
Outlook, Risks, and Contingencies
Management Commentary: The company notes an existing agreement with NIAID regarding the advanced development of Valortim as an anti-toxin therapeutic for inhalation anthrax.
Risks and Contingencies:
- The total contract value of $83.9 million is not guaranteed; it assumes all development milestones are met.
- Contract extensions are subject to NIAID's sole discretion.
- Funding is incremental, dependent on the achievement of specific milestones.
Investor Verification Checklist
- Verify the distinction between the registrant (PharmAthene, Inc.) and the company name provided in the request metadata (Altimmune, Inc.).
- Confirm the specific milestones required to trigger the fixed fee components of the $13.2 million base funding.
- Assess the probability of NIAID exercising the four optional periods, which constitute the majority of the potential $83.9 million value.
- Review the status of the separate Valortim agreement mentioned in the filing.